Clinical Trials
75 trialsMAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
panSOHO
Bayer
DP-04
AstraZeneca
STARTRK-2
Hoffmann-La Roche
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
STARTRK-NG
Hoffmann-La Roche
CLOVER-2
Cellectar Biosciences, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
CAMPERR
Adela, Inc
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
VARTUTRACE
Var2 Pharmaceuticals
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Daiichi Sankyo
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
PRESERVE-001
OncoC4, Inc.
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
PREFER
Labcorp Corporation of America Holdings, Inc
ROOT
Taproot Health
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
CAR
Shanghai PerHum Therapeutics Co., Ltd.
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
DUET-3
Xencor, Inc.
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Celon Pharma SA
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
A Study of PRT2527 in Participants With Advanced Solid Tumors
Prelude Therapeutics
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
LODESTAR
pharmaand GmbH
ALpha-T
Hoffmann-La Roche
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
REVEAL
Nektar Therapeutics
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics